FDA Chases Another Synthetic Stimulant Off Supplement Ingredient Menu
This article was originally published in The Tan Sheet
Executive Summary
CFSAN tells 14 firms the stimulant DMBA – identified by names including 1,3-dimethylbutylamine, 2-amino-4-methylpentane, AMP citrate and 4-methyl-2-pentanamine – has “no history of use or other evidence of safety … when used as a dietary ingredient.”
You may also be interested in...
Final Conviction In US FDA's Spiked-Supplement Investigation Of Blackstone Labs
James Boccuzzi was the last person sentenced in connection with FDA's investigation of sports supplement firm Blackstone Labs for selling steroid-containing supplements after it ignored agency's warning to stop.
DoJ Prosecutions: USPlabs Guilty, DMBA Firm Indicted From FDA Investigations
USPlabs executives, others plead guilty to felony charges stemming from marketing unsafe products labeled as supplements but containing DMAA and linked to hepatitis. Blackstone Labs and other firms indicted on felony charges following FDA investigation for marketing DMBA-containing products. "It's all very welcome news, but I'm not sure this is going to change the overall environment," says Pieter Cohen, a physician who advocates for tighter regulation of supplement manufacturing and marketing.
Hi-Tech Lawsuit Calls FDA DMAA Enforcement “Bullying Tactics”
Hi-Tech Pharmaceuticals files a lawsuit in federal court after receiving an administrative detention order from FDA to stop distributing its DMAA-containing products. The firm argues FDA should conduct a rulemaking to propose banning DMAA rather than ordering firms to stop using it.